Citius Oncology Q4 LYMPHIR Wholesaler Units Jump 120% to 792
CTXR sits 21% above its 52-week low of $0.37.
Summary
Citius Oncology reported preliminary Q4 FY2026 LYMPHIR unit sales to U.S. wholesalers of 792, up 120% from 360 in Q3, with 54 institutions now having ordered the drug versus 44 as of August 14, 2026.
Key Events · Earnings and Guidance · CTXR
-
Q4 LYMPHIR Units Up 120%
U.S. wholesalers purchased 792 units in the quarter ended September 30, 2026, versus 360 units in the quarter ended June 30, 2026.
-
Institutional Orders Reach 54
A total of 54 institutions have now ordered LYMPHIR, up from 44 as of August 14, 2026; management says it is more than halfway to its goal of formulary placement at 100 priority institutions by calendar year-end.
-
Vial Orders Roughly Flat
Prescribing centers ordered 950 LYMPHIR vials from wholesalers in Q4, versus 926 in Q3 — a much smaller increase than the wholesaler unit jump.
-
Preliminary, Unaudited Figures
The unit data is preliminary and unaudited and subject to year-end closing and audit; complete Q4 and FY2026 results are expected in December 2026 with the Form 10-K.
Analysis · CTXR · Life Sciences
The key takeaway is real commercial traction for LYMPHIR, now the company's main revenue engine: preliminary Q4 FY2026 wholesaler unit sales more than doubled sequentially, from 360 to 792, and the number of institutions that have ordered the drug rose from 44 in mid-August to 54. Against that, the parent, Citius Pharmaceuticals, carries a going concern warning and cash runway only into November 2026 per its last 10-Q, so the market will weigh whether this demand curve is steep enough to matter before the next financing. Note that the figures are unaudited and preliminary; full Q4 and FY2026 results are due in December 2026 with the 10-K.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTXR was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.37 to $1.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.